Ramipril

CHEMBL1168 Phase 4 अनुमोदित Small molecule

Half-Life

13-17 hours

Bioavailability

—

Protein Binding

—

Molecular Weight

416.5 g/mol

LogP

1.4

Phase

4

An ACE inhibitor used to treat high blood pressure, heart failure, and to reduce the risk of cardiovascular events in people with coronary artery disease. It works by relaxing blood vessels and reducing the workload on the heart.

आणविक भार

416.5120 g/mol

LogP

1.40

TPSA

95.90 Å²

लिपिंस्की RO5

उत्तीर्ण

चिकित्सीय क्षेत्र

Ovarian Cancer Alzheimer's Disease Migraine Systemic Lupus Erythematosus Chronic Kidney Disease Stroke Obesity Type 2 Diabetes Hypertension Breast Cancer Heart Failure Atrial Fibrillation Cardiovascular Disease

दवा वर्ग

C — C - Cardiovascular System

क्रिया का तंत्र

Prodrug converted to ramiprilat; ACE inhibitor.

Pharmacokinetics (PK)

Half-Life 13-17 hours

Pharmacodynamics (PD)

तंत्र

Prodrug converted to ramiprilat; ACE inhibitor.

2D संरचना

SVG PNG

Cite this structure

Embed this structure

SMILES

CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21

InChI

InChI=1S/C23H32N2O5/c1-3-30-23(29)18(13-12-16-8-5-4-6-9-16)24-15(2)21(26)25-19-11-7-10-17(19)14-20(25)22(27)28/h4-6,8-9,15,17-20,24H,3,7,10-14H2,1-2H3,(H,27,28)/t15-,17-,18-,19-,20-/m0/s1

Molecular Formula

C23H32N2O5

HBD / HBA

2 / 6

घूर्णनीय बंधन

10

भारी परमाणु

30

ACE (Angiotensin-Converting Enzyme) Inhibitor

Primary Target

ABCB1 (P-glycoprotein) Substrate

Major Ramipril + Lithium Carbonate

Ramipril, an ACE inhibitor, reduces lithium renal clearance through decreased glomerular filtration, leading to potentially toxic lithium accumulation.

Moderate Ramipril + Empagliflozin

Combining empagliflozin with an ACE inhibitor such as ramipril can cause additive blood pressure reduction and volume depletion, increasing the risk of hypotension and acute kidney injury.

No side effects recorded

Side effect data is not yet available for this drug.

अक्सर पूछे जाने वाले प्रश्न

An ACE inhibitor used to treat high blood pressure, heart failure, and to reduce the risk of cardiovascular events in people with coronary artery disease. It works by relaxing blood vessels and reducing the workload on the heart.

Prodrug converted to ramiprilat; ACE inhibitor.

Key pharmacokinetic parameters for Ramipril: Half-life: 13-17 hours.

Yes, Ramipril is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

Related Drugs

Same Drug Class

Atorvastatin Small molecule Amlodipine Small molecule Lisinopril Small molecule Metoprolol Small molecule

Same Target

Lisinopril Small molecule

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1168. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5362129. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

रोगी-अनुकूल जानकारी खोज रहे हैं?

Ramipril PillFYI पर

संरचना

त्वरित डेटा

Class: C - Cardiovascular System
सूत्र: C23H32N2O5
पर्यायवाची: 1

बाहरी लिंक

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

चिकित्सा अस्वीकरण

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.

Ramipril

चिकित्सीय क्षेत्र

दवा वर्ग

क्रिया का तंत्र

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D संरचना

Cite this structure

Embed this structure

No side effects recorded

अक्सर पूछे जाने वाले प्रश्न

Related Drugs

Same Drug Class

Same Target

References & Data Sources

Embed This Widget